OBJECTIVE: Hospital admissions for advanced chronic liver disease (ACLD) are associated with increased mortality, disability, a decline in quality of life and significant economic costs. Being admitted to the hospital usually indicates a triggering event that disrupted a previously stable condition, leading to decompensation or complications of ACLD. The most acute and severe manifestation of this imbalance is acute-on-chronic liver failure (ACLF), a syndrome representing a critical juncture. Reliable prognostic stratification of patients admitted with ACLF could facilitate the systematic delivery of tailored care, ranging from palliative care to intensive interventions like extracorporeal liver support devices and prioritised liver transplantation. Disease-specific prognostic tools, such as the Model for End-Stage Liver Disease score, are effective but have limitations, particularly in reflecting a patient's potential for recovery. The concept of the body's functional reserve in the context of ACLD/ACLF is gaining attention, with the Liver Frailty Index (LFI) potentially emerging as a recommended diagnostic tool. METHODS: Patients were selected from our cirrhosis registry (RH7). The LFI serves as an indicator of the patient's prognosis. The LFI measurement takes place at two time intervals: on the patient's admission and after 7 days of hospitalisation. RESULTS: Our RH7 registry included 154 patients (15.1%) who were diagnosed with ACLF. The primary cause of the underlying ACLD was alcohol-associated liver disease in the majority (79.8%) of cases. The mean value of LFI at admission was 4.50 (± 0.94). When patients with liver cirrhosis were categorised into three subgroups based on the LFI on day 7, survival exhibited a statistically significant decrease (p≤0.05) across all three ACLF grades. This decline in survival was observed from the 'improved LFI' cohort, through the 'stable LFI' group, to the 'worsened LFI' group. CONCLUSION: The impact of day 7 LFI on the survival of patients with ACLF is notable. Nevertheless, it does not markedly enhance the predictive capability of the LFI assessed on admission. Consequently, the initial LFI on day 1 continues to be the most valuable and commonly used instrument for promptly recognising individuals with ACLF.

Department of Hepatology Gastroenterology and Transplantation 2nd Department of Medicine Slovak Medical University Faculty of Medicine F D Roosevelt Hospital Banska Bystrica Slovakia

Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague and Teaching Thomayer Hospital Prague Czech Republic

F D Roosevelt University Hospital of Banská Bystrica Banská Bystrica Slovakia

Faculty of Sport Science and Health Matej Bel University Banska Bystrica Slovakia

See more in PubMed

Sepanlou SG, Safiri S, Bisignano C. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–66. doi: 10.1016/S2468-1253(19)30349-8. PubMed DOI PMC

Costa D, Simbrunner B, Jachs M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021;74:819–28. doi: 10.1016/j.jhep.2020.10.004. PubMed DOI

Zhou W-C, Zhang Q-B, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20:7312–24. doi: 10.3748/wjg.v20.i23.7312. PubMed DOI PMC

Shearer JE, Jones R, Parker R, et al. The Natural History of Advanced Chronic Liver Disease Defined by Transient Elastography. Clin Gastroenterol Hepatol. 2023;21:694–703. doi: 10.1016/j.cgh.2022.03.015. PubMed DOI

Canillas L, Pelegrina A, Álvarez J, et al. Clinical Guideline on Perioperative Management of Patients with Advanced Chronic Liver Disease. Life (Basel) 2023;13:132. doi: 10.3390/life13010132. PubMed DOI PMC

Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019;70:151–71. doi: 10.1016/j.jhep.2018.09.014. PubMed DOI

Moon D-B, Lee S-G. Liver transplantation. Gut Liver. 2009;3:145–65. doi: 10.5009/gnl.2009.3.3.145. PubMed DOI PMC

Marroni CA, Fleck AM, Jr, Fernandes SA, et al. Liver transplantation and alcoholic liver disease: History, controversies, and considerations. World J Gastroenterol. 2018;24:2785–805. doi: 10.3748/wjg.v24.i26.2785. PubMed DOI PMC

Fernández-Alonso V, Hernández-Matías AM, Díaz-Serrano MT, et al. Analysis of the impact of liver transplantation as a condition of health. Enferm Clin (Engl Ed) 2022;32:249–56. doi: 10.1016/j.enfcle.2022.03.005. PubMed DOI

Skladaný Ľ, Adamcová Selčanová S, Janičko M, et al. Acute decompensation (AD) of advanced chronic liver disease (ACLD) and hepatitis E virus (HEV) infection as the trigger. Klin Mikrobiol Infekc Lek. 2018;24:82–7. PubMed

Simbrunner B, Caparrós E, Neuwirth T, et al. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response. Hepatol Int. 2023;17:1045–56. doi: 10.1007/s12072-023-10496-y. PubMed DOI PMC

Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–37. doi: 10.1053/j.gastro.2013.02.042. PubMed DOI

Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56. doi: 10.1093/gerona/56.3.m146. PubMed DOI

Kamath PS, Kim WR, Advanced Liver Disease Study Group The model for end-stage liver disease (MELD) Hepatology. 2007;45:797–805. doi: 10.1002/hep.21563. PubMed DOI

Roth JA, Chrobak C, Schädelin S, et al. MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients. Medicine (Baltimore) 2017;96:e7155. doi: 10.1097/MD.0000000000007155. PubMed DOI PMC

Tsoris A, Marlar CA. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Use of the child pugh score in liver disease. PubMed

Moreno R, Rhodes A, Piquilloud L, et al. The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update? Crit Care. 2023;27:15. doi: 10.1186/s13054-022-04290-9. PubMed DOI PMC

Haj Ali S, Abu Sneineh A, Hasweh R. Nutritional assessment in patients with liver cirrhosis. World J Hepatol. 2022;14:1694–703. doi: 10.4254/wjh.v14.i9.1694. PubMed DOI PMC

Jehan FS, Pandit V, Khreiss M, et al. Frailty Predicts Loss of Independence After Liver Surgery. J Gastrointest Surg. 2022;26:2496–502. doi: 10.1007/s11605-022-05513-8. PubMed DOI

Laube R, Wang H, Park L, et al. Frailty in advanced liver disease. Liver Int. 2018;38:2117–28. doi: 10.1111/liv.13917. PubMed DOI

Naimimohasses S, O’Gorman P, McCormick E, et al. Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2022;9:e000861. doi: 10.1136/bmjgast-2021-000861. PubMed DOI PMC

Kremer WM, Nagel M, Reuter M, et al. Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis. Clin Transl Gastroenterol. 2020;11:e00211. doi: 10.14309/ctg.0000000000000211. PubMed DOI PMC

Saraswat VA, Kumar K. Untangling the Web of Malnutrition, Sarcopenia, and Frailty in Chronic Liver Disease. J Clin Exp Hepatol. 2022;12:268–71. doi: 10.1016/j.jceh.2022.02.002. PubMed DOI PMC

Zuberi BF, Rasheed T, Ali FS, et al. Assessment of frailty in cirrhosis using bedside measures and its correlation with Child-Turcotte-Pugh, MELD & MELD-Na Scores. Pak J Med Sci. 2022;38:1086–92. doi: 10.12669/pjms.38.5.5545. PubMed DOI PMC

Lang P-O, Michel J-P, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009;55:539–49. doi: 10.1159/000211949. PubMed DOI

Roh E, Hwang SY, Yoo HJ, et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study. Hepatol Int. 2022;16:545–54. doi: 10.1007/s12072-021-10258-8. PubMed DOI

Siyu L, Yuan Y, Ran A, et al. Frailty as tested by the Liver Frailty Index in out-patient patients with cirrhosis in China: a cross-sectional study. Eur J Gastroenterol Hepatol. 2023;35:440–4. doi: 10.1097/MEG.0000000000002502. PubMed DOI

Klein CG, Malamutmann E, Latuske J, et al. Frailty as a predictive factor for survival after liver transplantation, especially for patients with MELD≤15-a prospective study. Langenbecks Arch Surg. 2021;406:1963–9. doi: 10.1007/s00423-021-02109-9. PubMed DOI PMC

Lai JC, Shui AM, Duarte-Rojo A, et al. Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. Hepatology. 2022;75:1471–9. doi: 10.1002/hep.32268. PubMed DOI PMC

Lin F-P, Visina JM, Bloomer PM, et al. Prehabilitation-Driven Changes in Frailty Metrics Predict Mortality in Patients With Advanced Liver Disease. Am J Gastroenterol . 2021;116:2105–17. doi: 10.14309/ajg.0000000000001376. PubMed DOI

Singh S, Taneja S, Tandon P, et al. A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis. J Clin Exp Hepatol. 2022;12:398–408. doi: 10.1016/j.jceh.2021.07.003. PubMed DOI PMC

Soto R, Díaz LA, Rivas V, et al. Frailty and reduced gait speed are independently related to mortality of cirrhotic patients in long-term follow-up. Ann Hepatol. 2021;25:100327. doi: 10.1016/j.aohep.2021.100327. PubMed DOI

Lanthier N, Stärkel P, Dahlqvist G. Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible? Clin Res Hepatol Gastroenterol. 2021;45:101661. doi: 10.1016/j.clinre.2021.101661. PubMed DOI

Kao J, Reid N, Hubbard RE, et al. Frailty and solid-organ transplant candidates: a scoping review. BMC Geriatr. 2022;22:864. doi: 10.1186/s12877-022-03485-7. PubMed DOI PMC

Lai JC, Dodge JL, Kappus MR, et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020;73:575–81. doi: 10.1016/j.jhep.2020.03.029. PubMed DOI PMC

Ha NB, Fan B, Shui AM, et al. CT-quantified sarcopenic visceral obesity is associated with poor transplant waitlist mortality in patients with cirrhosis. Liver Transpl. 2023;29:476–84. doi: 10.1097/LVT.0000000000000010. PubMed DOI PMC

Iacob S, Mina V, Mandea M, et al. Assessment of Sarcopenia Related Quality of Life Using SarQoL® Questionnaire in Patients With Liver Cirrhosis. Front Nutr. 2022;9:774044. doi: 10.3389/fnut.2022.774044. PubMed DOI PMC

Englesbe MJ, Patel SP, He K, et al. Sarcopenia and Post-Liver Transplant Mortality. J Am Coll Surg. 2010;211:271–8. doi: 10.1016/j.jamcollsurg.2010.03.039. PubMed DOI PMC

Wang S, Whitlock R, Xu C, et al. Frailty is associated with increased risk of cirrhosis disease progression and death. Hepatology. 2022;75:600–9. doi: 10.1002/hep.32157. PubMed DOI

Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66:564–74. doi: 10.1002/hep.29219. PubMed DOI PMC

Lai JC, Covinsky KE, McCulloch CE, et al. The Liver Frailty Index Improves Mortality Prediction of the Subjective Clinician Assessment in Patients With Cirrhosis. Am J Gastroenterol. 2018;113:235–42. doi: 10.1038/ajg.2017.443. PubMed DOI PMC

Wang CW, Lebsack A, Chau S, et al. The Range and Reproducibility of the Liver Frailty Index. Liver Transpl. 2019;25:841–7. doi: 10.1002/lt.25449. PubMed DOI PMC

Wang M, Shui AM, Ruck J, et al. Clinically relevant cut-points for changes in the Liver Frailty Index are associated with waitlist mortality in patients with cirrhosis. Liver Transpl. 2024;30:991–1001. doi: 10.1097/LVT.0000000000000418. PubMed DOI PMC

Ge J, Kim WR, Lai JC, et al. “Beyond MELD” - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. J Hepatol. 2022;76:1318–29. doi: 10.1016/j.jhep.2022.03.003. PubMed DOI PMC

Hernaez R, Solà E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–53. doi: 10.1136/gutjnl-2016-312670. PubMed DOI PMC

Kumar R, Mehta G, Jalan R. Acute-on-chronic liver failure. Clin Med (Lond) 2020;20:501–4. doi: 10.7861/clinmed.2020-0631. PubMed DOI PMC

Shah NJ, Mousa OY, Syed K, et al. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Acute on chronic liver failure. PubMed

Skladany L, Molcan P, Vnencakova J, et al. Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis. Can J Gastroenterol Hepatol. 2021;2021:5576531. doi: 10.1155/2021/5576531. PubMed DOI PMC

Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1611–44. doi: 10.1002/hep.32049. PubMed DOI PMC

Skladany L, Drotarova Z, Vnencakova J, et al. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. Croat Med J. 2021;62:8–16. doi: 10.3325/cmj.2021.62.8. PubMed DOI PMC

Guo G, Li C, Hui Y, et al. Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis. Ther Adv Chronic Dis. 2022;13:20406223221109651. doi: 10.1177/20406223221109651. PubMed DOI PMC

Trivedi HD, Tapper EB. Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterol Rep (Oxf) 2018;6:13–20. doi: 10.1093/gastro/gox042. PubMed DOI PMC